
Please try another search
One pharmaceutical stock that has been declining recently is Bristol-Myers Squibb (NYSE:BMY). Earlier this week, the company announced a takeover of Celgene (NASDAQ:CELG) for $74 billion. As often happens when a company buys another firm, BMY stock fell on the news. Many traders and investors are now wondering where the stock should now trade. One level that looks solid on the charts is around $40, which is a major retrace level and where a breakout took place in March 2013. Generally, these factors will cause the institutional money to step in and defend the stock around this price point.
Stocks finished lower yesterday, following more hawkish-than-expected projections from the Fed for 2024 and 2025. The Fed anticipates rates to be at 5.1% by the end of 2024,...
The S&P 500 shed 1% after the Fed kept interest rates unchanged. That non-move was widely expected, so stocks were not responding to the September rate decision but to what the Fed...
Delivery service provider Instacart saw its share price tumble 18% since the Monday market debut. Following Arm’s debut, shares of Instacart surged more than 40% at their initial...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.